Overview
ZVRA market data
Price History
ZVRA price chart · 1M
- O
- 11.74
- H
- 11.89
- L
- 11.63
- C
- 11.85
- Vol
- 27,714.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $11.74
- Previous Close
- $11.75
- Day High
- $11.89
- Day Low
- $11.63
- 52 Week High
- $15.04
- 52 Week Low
- $9.12
- 7 Day Return
- -0.50%
- 30 Day Return
- +21.79%
- 90 Day Return
- +1.98%
- 1 Year Return
- +22.61%
- Daily Notional Volume
- $328.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 11.89 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.45 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.97 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 42.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.16 – $15.04 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $692.7M · P/B 3.26 · P/S 5.09.
Company News
Zevra Therapeutics To Present Two Posters Featuring Long-Term Real-World Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At SSIEM Annual SymposiumBenzinga · Aug 25, 2026, 11:33 AM
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price TargetBenzinga · Aug 20, 2026, 11:25 AM
Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23Benzinga · Aug 7, 2026, 5:10 PM
Zevra Therapeutics shares are trading higher after Citizens raised its price target on the stock from $25 to $28.Benzinga · Aug 6, 2026, 3:05 PM
Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28Benzinga · Aug 6, 2026, 1:14 PM
Zevra Therapeutics Says Expects To Continue Engagement With The U.S. FDA In The H2 2026 To Explore Pathways To Accelerate Clinical DevelopmentBenzinga · Aug 5, 2026, 11:26 PM
UPDATE: Zevra Therapeutics Q2 Adj. EPS $0.25 Beats $0.14 Estimate, Sales $39.663M Beat $33.572M EstimateBenzinga · Aug 5, 2026, 9:56 PM
Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M EstimateBenzinga · Aug 5, 2026, 8:23 PM
8-K filing — ZEVRA THERAPEUTICS, INC. (ZVRA)SEC EDGAR · Aug 5, 2026, 8:13 PM
Zevra Therapeutics Announces Publication Of "Long-Term Real-World Safety And Effectiveness Of Arimoclomol In Individuals With NPC: Outcomes From US Early Access Program Over A 4-Year Period" In Molecular Genetics And MetabolismBenzinga · Aug 3, 2026, 11:34 AM